Market Overview

Asia-Pacific Conjugate Vaccine Market Report 2018: Analysis & Outlook to 2023 - A $66.6 Billion Opportunity -


The "Asia-Pacific
Conjugate Vaccine Market (2018-2023)"
report has been added to's

Asia-Pacific is the fastest growing market for conjugate vaccines. The
conjugate vaccines market in Asia-Pacific is expected to expand at a
CAGR of 23.5%, leading to a revenue of USD 66.61 Bn by 2023. By volume,
it is anticipated to reach 6,883.55 Million units by 2023, expanding at
a CAGR of 21.87%.

A penetration rate of around 95% of DTP conjugate vaccines indicates an
excellent coverage in Asia-Pacific countries and very little is left to
achieve full penetration for the vaccines. Countries with high
populations such as China and India, serve as major target areas for
such vaccines, and the introduction of these vaccines would ensure a
disease-free society.

Key Growth Factors

The Asia-Pacific has a growing market owing to improvement and
advancements in medical science. Awareness about availability of higher
number of vaccines as compared to before are major driving factors for
the growth of this market.

The primary indicators of the potential for the vaccine market are the
geriatric population in Asia and its growth in some countries such as
India and China. This has encouraged market participants to increase
spending on research and development, and distribution facilities in
Asian countries.


The Asia-Pacific Conjugate Vaccine market is expected to grow at a
significant rate. But there are issues with regard to health care access
and costs. Fragmented health care has a negative impact on the
effectiveness of any proposed immunization strategy. Adolescent and
adult pertussis is under-recognized by lay and medical communities due
to its unique clinical presentation.

Key Players

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur

Other Prominent Players

  • CSL Limited
  • Bharat Biotech
  • Biological E. Limited
  • Serum Institute of India

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Market Overview

Chapter 3: Asia-Pacific Major Segment Overview - by Disease Indication

Chapter 4: Asia-Pacific Major Segment Overview - by End-User

Chapter 5: China - by Disease Indication

Chapter 6: China - by End-User

Chapter 7: India - by Disease Indication

Chapter 8: India - by End-User

Chapter 9: Japan - by Disease Indication

Chapter 10: Japan - by End-User

Chapter 11: South Korea - by Disease Indication

Chapter 12: South Korea - by End-User

Chapter 13: Competitive Landscape

For more information about this report visit

View Comments and Join the Discussion!